Positive phase II RCT data for Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate

Interim data (n=722) reported 95% to 100% seroconversion following a second injection in all age groups (18 to 95 years old), with higher response in adults aged 18 to 59 years old. There was acceptable tolerability and no safety concerns.

Source:

Biospace Inc.